Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations

Autores da FMUP
Participantes de fora da FMUP
- Reichmann, H
- Eggert, K
- Oehlwein, C
- Warnecke, T
- Lees, AJ
- Kemmer, M
Unidades de investigação
Abstract
Introduction: The OPTIPARK study confirmed the effectiveness and safety of opicapone as adjunct therapy to levodopa in patients with Parkinson's disease (PD) and motor fluctuations under real-world conditions. The aim of this sub-analysis was to evaluate opicapone in the German patient cohort of OPTIPARK in order to provide country-specific data. Methods: OPTIPARK was an open-label, single-arm study conducted in routine clinical practice across Germany and the UK. Patients with PD and motor fluctuations received once-daily opicapone 50 mg for 3 months in addition to levodopa. The primary endpoint was Clinicians' Global Impression of Change (CGI-C). Secondary assessments included Patients' Global Impressions of Change (PGI-C), Unified Parkinson's Disease Rating Scale (UPDRS) I-IV, Parkinson's Disease Questionnaire (PDQ-8), and Non-Motor Symptoms Scale (NMSS). This sub-analysis reports outcomes from the German patients only. Results: Overall, 363 (97.6%) of the 372 patients included in the German cohort received >= 1 dose of opicapone and 291 (80.2%) completed the study. Improvements on CGI-C and PGI-C were reported by 70.8% and 76.3% of patients, respectively. UPDRS scores improved for activities of daily living during OFF time by -3.3 +/- 4.5 points and motor scores during ON time by -5.3 +/- 7.9 points. PDQ-8 and NMSS scores also demonstrated improvements. Treatment emergent adverse events considered at least possibly related to opicapone occurred in 37.7% of patients, with most being of mild or moderate intensity. Conclusion: Opicapone added to levodopa in patients with PD and motor fluctuations was effective and generally well tolerated in routine clinical practice across Germany.
© 2022 The Author(s). Published by S. Karger AG, Basel.
Dados da publicação
- ISSN/ISSNe:
- 1421-9913, 0014-3022
- Tipo:
- Article
- Páginas:
- 389-397
- DOI:
- 10.1159/000523771
- Link para outro recurso:
- www.scopus.com
European Neurology S. Karger AG
Citações Recebidas na Web of Science: 1
Citações Recebidas na Scopus: 2
Documentos
- Não há documentos
Filiações
Keywords
- Levodopa; Motor fluctuations; Opicapone; Parkinson's disease; Real-world study
Financiamento
Proyectos asociados
Modelling Propofol pharmacokinetics and pharmacodynamics during an intravenous anaesthesia guided by the bispectral index (Bis)
Investigador Principal: Patrício Manuel Vieira Araújo Soares da Silva
Estudo Clínico Académico . 2021
Inervação simpática e mecanismos adrenérgicos locais na regulação funcional da córnea
Investigador Principal: Patrício Manuel Vieira Araújo Soares da Silva
Estudo Clínico Académico . 2019
Citar a publicação
Reichmann H,Eggert K,Oehlwein C,Warnecke T,Lees AJ,Kemmer M,Soares P. Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations. Eur. Neurol. 2022. 85. (5):p. 389-397. IF:2,400. (3).